Acusphere reports results from Imagify phase III trials

AuntMinnie.com staff writers
May 3, 2007

Ultrasound contrast developer Acusphere said that its Imagify (perflubutane polymer microspheres) contrast agent exceeded the criteria in accuracy and sensitivity in its second phase III clinical trial of the product.

The Watertown, MA-based company will use the results to support a new drug application (NDA) submission for Imagify in the fourth quarter of this year. The agent is designed to assess perfusion.

By AuntMinnie.com staff writers
May 4, 2007

Related Reading

Acusphere taps Bucceri for regulatory post, February 5, 2007

Acusphere to raise $23 million, December 7, 2006

Acusphere names Jaffe as VP, September 21, 2006

Acusphere licenses US contrast technology rights from GE, June 6, 2006

Acusphere to raise $38 million, April 7, 2006

Copyright © 2007 AuntMinnie.com

Latest in Ultrasound
Back Pain 400
Elastography shows tissue stiffness in athletes with low-back pain
November 22, 2024
Ovarian Cancer Social
Nomogram model predicts malignancy risk in ovarian masses
November 19, 2024
Heart Plaque
AI-enabled CCTA on par with IVUS for plaque quantification
November 14, 2024
Emergency 400
Ultrasound-guided nerve blocks safe for emergency pain management
November 13, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2007 04 03 14 27 03 706
Ultrasound
US is best bet in male breast, but only if imaging is absolutely necessary
2007 02 05 15 40 53 706
Ultrasound
Ultrasound continues to make inroads in breast imaging
2006 12 20 15 29 47 706
Ultrasound
Microflow imaging may boost prostate biopsy yield
More in Ultrasound
Elastography shows tissue stiffness in athletes with low-back pain
By Amerigo Allegretto
Shear-wave elastography shows tissue stiffness in athletes with low-back pain, which could help guide rehabilitation strategies.
November 22, 2024
Back Pain 400
Nomogram model predicts malignancy risk in ovarian masses
By Amerigo Allegretto
A nomogram model based on O-RADS ultrasound findings and clinical and lab indicators can predict malignancy risk in adnexal cystic-solid masses.
November 19, 2024
Ovarian Cancer Social
AI-enabled CCTA on par with IVUS for plaque quantification
By Kate Madden Yee
An AI-powered automated plaque quantification tool for coronary CT angiography (CCTA) performs on par with intravascular ultrasound (IVUS) for quantifying heart plaque volume and characterizing plaque.
November 14, 2024
Heart Plaque
Ultrasound-guided nerve blocks safe for emergency pain management
By Amerigo Allegretto
Ultrasound-guided nerve blocks (UGNBs) performed by emergency clinicians could be safe for pain management.
November 13, 2024
Emergency 400
Thermal ablation effective long term in patients with thyroid cancer
By Will Morton
Outcomes over 10 years suggest that image-guided thermal ablation is a safe and effective option for patients with papillary thyroid carcinoma.
November 7, 2024
Thyroid Cancer
Could cranial ultrasound sub for brain MRI in imaging infants?
By Amerigo Allegretto
Cranial ultrasound could have utility for imaging infants with hypoxic-ischemic encephalopathy.
November 6, 2024
Baby Bottle
Ultrasound nonmass breast lesion features may signal malignancy
By Amerigo Allegretto
Some nonmass breast lesion characteristics on ultrasound exams can be considered suspicious for malignancy at screening ultrasound.
November 5, 2024
Images depict a 43-year-old woman with a malignant nonmass lesion that was diagnosed as microinvasive ductal carcinoma. (A) Transverse and (B) longitudinal ultrasound images show a hypoechoic nonmass lesion (solid arrows) with segmental distribution in the left breast. The lesion has associated calcifications (dashed arrows in A). (C) Longitudinal color Doppler ultrasound image shows high vascularity. (D) Magnified image in the mediolateral oblique view from screening mammography shows grouped calcifications (arrows), which are considered a mammographic correlate of the ultrasound-detected nonmass lesion (A radiopaque marker attached to the skin is visible in the image because the mammographic exam was performed after screening breast ultrasound). Ultrasound-guided core needle biopsy and pathologic examination revealed ductal carcinoma in situ, but the lesion was upgraded to microinvasive ductal carcinoma at subsequent surgery (2.5-cm ductal carcinoma in situ, histologic grade II, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor type 2-negative).
ChatGPT demonstrates mixed results in assigning BI-RADS categories
By Amerigo Allegretto
ChatGPT achieves modest accuracy when assigning BI-RADS scores for mammograms and breast ultrasound exams.
November 1, 2024
Chat Gpt 400
ABUS screening improves breast cancer screening in low-resource areas
By Amerigo Allegretto
Automated breast ultrasound (ABUS) with remote reading may improve access to breast cancer screening and early detection in low-resource settings.
October 29, 2024
Ultrasound Breast 400
Ukraine's top pediatric hospital rebuilds after bomb attack
By Philip Ward
Radiology staff at the Ohmatdyt Children's Hospital in Kyiv are making steady progress with their plan to restore normal service after a devastating missile attack.
October 25, 2024
Thanks to the support of the global imaging community, radiology staff at the Ohmatdyt can now look forward to restoring normal service.
CNN models using ultrasound images detect pancreatic neoplasms
By Amerigo Allegretto
A deep-learning method using endoscopic ultrasound images could detect pancreatic neuroendocrine neoplasms.
October 18, 2024
Ultrasound Scanner Computerized 400
Ultrasound method detects cellular rejection in liver transplant cases
By Amerigo Allegretto
An ultrasound measurement technique could detect and stage acute cellular rejection in liver transplant patients.
October 16, 2024
Ultrasound Diagnostic Control Panel
Page 1 of 512
Next Page